These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 35371982)
21. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres. La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896 [TBL] [Abstract][Full Text] [Related]
22. Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation. Hassan U; Latif M; Yousaf I; Bin Anees S; Mushtaq S; Akhtar N; Loya A Cureus; 2021 Aug; 13(8):e17267. PubMed ID: 34540489 [TBL] [Abstract][Full Text] [Related]
23. High frequency of H3 K27M mutations in adult midline gliomas. Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375 [TBL] [Abstract][Full Text] [Related]
24. Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis. Daoud EV; Rajaram V; Cai C; Oberle RJ; Martin GR; Raisanen JM; White CL; Foong C; Mickey BE; Pan E; Hatanpaa KJ J Neuropathol Exp Neurol; 2018 Apr; 77(4):302-311. PubMed ID: 29444279 [TBL] [Abstract][Full Text] [Related]
25. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma. Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914 [TBL] [Abstract][Full Text] [Related]
26. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894 [TBL] [Abstract][Full Text] [Related]
27. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma. Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690 [TBL] [Abstract][Full Text] [Related]
28. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820 [TBL] [Abstract][Full Text] [Related]
29. Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report. Fomchenko EI; Erson-Omay EZ; Kundishora AJ; Hong CS; Daniel AA; Allocco A; Duy PQ; Darbinyan A; Marks AM; DiLuna ML; Kahle KT; Huttner A J Neurosurg Pediatr; 2020 Feb; 25(2):121-130. PubMed ID: 31653819 [TBL] [Abstract][Full Text] [Related]
30. Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas. Kandemirli SG; Kocak B; Naganawa S; Ozturk K; Yip SSF; Chopra S; Rivetti L; Aldine AS; Jones K; Cayci Z; Moritani T; Sato TS World Neurosurg; 2021 Jul; 151():e78-e85. PubMed ID: 33819703 [TBL] [Abstract][Full Text] [Related]
31. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Abe H; Natsumeda M; Okada M; Watanabe J; Tsukamoto Y; Kanemaru Y; Yoshimura J; Oishi M; Hashizume R; Kakita A; Fujii Y Front Oncol; 2019; 9():1568. PubMed ID: 32039031 [TBL] [Abstract][Full Text] [Related]
32. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases. Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860 [TBL] [Abstract][Full Text] [Related]
33. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report. Wang Q; Niu W; Pan H Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950 [TBL] [Abstract][Full Text] [Related]
35. Detection of H3K27M mutation in cases of brain stem subependymoma. Yao K; Duan Z; Wang Y; Zhang M; Fan T; Wu B; Qi X Hum Pathol; 2019 Feb; 84():262-269. PubMed ID: 30389438 [TBL] [Abstract][Full Text] [Related]
36. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival. Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221 [TBL] [Abstract][Full Text] [Related]
37. H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients. Hu XM; Nie XY; Xu KL; Wang Y; Tang F; Du ZG; Xiong J Front Oncol; 2022; 12():912166. PubMed ID: 35756637 [TBL] [Abstract][Full Text] [Related]
38. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas. Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280 [TBL] [Abstract][Full Text] [Related]
39. Adult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: Case report and review of the literature. Yekula A; Gupta M; Coley N; U HS Int J Surg Case Rep; 2020; 68():124-128. PubMed ID: 32145563 [TBL] [Abstract][Full Text] [Related]